Tagomics

Don't miss The Connectivity Mix, taking place in Birmingham on 17th October! Fantastic to see Jack Kennewick, Co-founder and CEO of Milner Affiliate Tagomics in the speaker line-up 👏👇

Welcome to the team Paulina Siejka-Zielinska! 🎉 Paulina holds a DPhil in Clinical Medicine from the University of Oxford and has extensive postdoctoral experience. Her background combines a strong foundation in epigenetics, liquid biopsy and sequencing assay development with computational skills. During her DPhil, she contributed to the development of novel methods for analysing DNA methylation, including TAPS technology. She successfully used TAPS data to develop computational approaches for predicting cancer from epigenetic and fragmentomic signatures in circulating plasma DNA. In her postdoctoral research, she applied integrative data analysis to deconvolute fine interplay between the epigenome and transcriptome in colonic premalignancy. Her computational experience encompasses diverse datasets such as methylation sequencing, RNA-seq and single-cell omics data. We are excited to welcome Paulina to the team. Her comprehensive understanding of epigenetics and advanced computational skills will unveil the rich biological insights offered by Tagomics' platform. #Welcome #Tagomics #Team

Tagomics Summer Day Out ☀️ Sorry for our slow reply, we were busy punting, picnicking and playing (competing...) in sunny Cambridge! #TeamBuilding #Teamwork #TagTeam

Welcome to the team Nana Mensah! Nana has just completed his PhD in Computational Biology from the Francis Crick Institute and University College London. He developed bioinformatics tools to investigate aberrant DNA methylation in cancers and applied these to studies of advanced prostate cancers, small intestinal neuroendocrine tumours and non small-cell lung cancers. Before embarking on his PhD, he completed the three-year NHS scientist training programme in Clinical Bioinformatics, where he developed bioinformatics pipelines for the rare disease service at Guy’s and St Thomas’ NHS Foundation Trust. We're delighted to have Nana on the team! His skillset will feed into the development of our multiomic biomarker discovery and clinical reporting software. #Welcome #Tagomics #Healthcare #Innovation

Welcome to the team Peter Bream! Peter is a graduate engineer and Chartered Accountant. He has 30 years’ experience in international business and has been CFO in listed (LSE and NASDAQ), PE and VC environments ranging in scale from start-up to £2 Billion. Sectors include biotech, pharmaceuticals, medical diagnostics, analytical laboratory services, chemicals and engineering. His geographically global business responsibilities have been broad and included procurement, manufacturing, IT and business development. He has extensive experience in corporate transactions and the realization of value through sale and exit. We're thrilled to have Peter on board. His deep financial, strategic, and commercial expertise will greatly contribute to our company's growth.

Welcome to the team, Stephen Evens! Stephen holds a Master’s Degree in Mathematics from the University of Reading and has over eight years of experience developing, managing, and assuring scientific software in regulated environments. For the past three years, Stephen has been working as a Staff Bioinformatics Engineer at Exact Sciences, where he helped develop the TAPS methylation technology and led the production pipeline development of the Oncodetect MRD test. We are delighted to welcome Stephen to the team. He will lead our bioinformatics engineering function, enhancing our computational infrastructure and advancing our software development.

Connect with our Chair, Dr. Kirk Malloy, and CEO, Dr. Jack Kennefick, at the American Society of Clinical Oncology Annual Meeting #ASCO24. Discover how #Tagomics' innovative multiomic platform can revolutionise your drug discovery and development pipelines. Reach out to schedule a meeting! #Biomarkers #DrugDevelopment #ClinicalTrials #Diagnostic #Multiomic #CancerResearch

We are delighted to join Nucleate and IQ Capital for an evening of game-changing insights and engaging networking.   Our CTO Debora Lucarelli will join a fantastic panel of speakers exploring the next-generation of sequencing technologies and applications. Together with Peter Crane and Alisandra Denton, the panel will delve into emerging trends, cutting-technologies and the latest scientific advances.    Our CEO Jack Kennefick is attending the networking session and is looking forward to connecting to the many tech focused entrepreneurs and investors attending.    🏁 Key Event Details 🏁 🗓 Tuesday, May 28th 🔗 RSVP Here - https://lu.ma/xfa8h525

Welcome to the team, Lylia Ouboussad! 🎉 Lylia holds a PhD in cancer genetics from Brunel University and has extensive experience as a postdoctoral research fellow at the University of Leeds. Her initial postdoctoral project focused on the epigenetics of myeloid differentiation within the experimental haematology section. Subsequently, she investigated the pathogenesis of rheumatoid arthritis, analysing treatment responses to biologics-based therapies by assessing the epigenetics/cell signalling pathway profiles of patients involved in clinical trials. After a decade in academia, Lylia transitioned to the cell and gene therapy sector. Initially, she contributed to Achilles Therapeutics as a Translational Senior Scientist, concentrating on characterising novel clonal neoantigen products. She then moved to Quell Therapeutics, a CAR T-regulatory T cells (T-regs) company, assuming the role of Senior Scientist. In this capacity, she led the immune monitoring team and oversaw translational operations. We're delighted to welcome Lylia as our Clinical Study Coordinator. Her role will involve designing and managing the clinical studies essential for the development of our products. #Welcome #Tagomics #Team

Want to learn more about Tagomics’ approach in uncovering disease-associated biomarkers via epigenomic profiling?   The latest Enseqlopedia blog post by James Hadfield features Tagomics recent pre-print on how ‘Active-Seq’, the company’s fast epigenetic profiling platform, can be utilised to achieve genome-wide profiling with low DNA input from cell lines, liquid biopsies and formalin-fixed paraffin embedded (FFPE) tissue.   Read more below👇